READI
Project information
Full title: Research in Europe and Diversity Inclusion (READI)
Duration: 72 months (1 January 2025 – 31 December 2030)
Status: Ongoing
Funding programme: The project is a HORIZON JU Research and Innovation Action co-funded by the European Union, under HORIZON-JU-IHI-2023-04-two-stage.
What will the project do?
Clinical studies often fail to represent underserved and underrepresented communities, leading to health disparities and knowledge gaps. The READI consortium aims to create a patient-centred, inclusive clinical study ecosystem by connecting stakeholders, providing training, and breaking down barriers to participation.
Central to READI’s approach is a sustainable, patient-focused digital platform to improve access to clinical study information, tools, and resources while fostering collaboration. READI will test its tools in four clinical studies, addressing challenges such as mistrust and lack of information.
What are the expected outcomes?
- Helping underserved and underrepresented communities overcome clinical studies’ participation barriers (e.g., lack of information/awareness, mistrust, poor communication, geographic limitations, prejudice)
- Improving understanding of diseases and conditions, preventative care, and treatment effectiveness across various demographic groups, leading to better health outcomes for society as a whole.
- Creating a well-connected ecosystem involving patients, researchers, healthcare professionals, and community organisations to collaboratively improve clinical research practices.
- Creating a sustainable, innovative, and open-access platform that provides tools, training, and information to support clinical study engagement and patient-community connections.
What is EPFs’ role?
-
EPF will activate the patient community and will hold a central role in communicating and disseminating project results to a wider audience to promote awareness among citizens and patients' communities, and to maximise the impact of the overall activities of the READI project.
The consortium
The consortium is led by the Servicio Madrileño de Salud and composed of 73 partners from 18 countries:
- Servicio Madrileño de Salud
- Fundación para la Investigación Biomédica del Hospital Universitario La Paz
- Fundación para la Investigación Biomédica del Hospital Universitario de Getafe
- The Synergist
- European University Cyprus Ltd
- Information Technology for Translational Medicine (ITTM)
- European Clinical Research Infrastructure Network (ECRIN)
- Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer
- Stichting EUPATI
- Klinikum der Universität zu Köln
- Aarhus Universitet
- Aarhus Universitetshospital
- Midtjyllands EU-Kontor Forening
- CDISC Europe
- Esperity
- CureWiki
- Digestive Cancers Europe (DiCE)
- European AIDS Treatment Group.
- European Patients' Forum
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
- Fundación 29 de Febrero
- Fundació Privada per a la Recerca i la Docència Sant Joan de Déu
- Global Heart Hub
- HL7 International
- Irish Platform for Patients' Organisations, Science and Industry (IPPOSI)
- Nacionalinis Vėžio Institutas
- Penta
- Pagalbos Onkologiniams Ligoniams Asociacija
- Shine 2Europe
- SocialIT Software e Consulting
- Synapse
- Trial Nation
- Universitair Medisch Centrum Utrecht
- Centro de Tecnologías de Interacción Visual y Comunicaciones Vicomtech
- Stichting VU
- Youth Cancer Europe
- Zabala Innovation
- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline Research & Development (GSK)
- Breakthrough T1D
- Janssen-Cilag Limited
- Janssen-Cilag GmbH
- Janssen Biologics BV
- Janssen Pharmaceutica NV
- Eli Lilly and Company
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Novartis Pharma
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Takeda Pharmaceuticals
- UCB Biopharma
- Chiesi Farmaceutici SpA
- Boehringer Ingelheim International
- Almirall
- EDEX - Educational Excellence
- Eli Lilly and Company Ltd
- Lilly Deutschland GmbH
- Pfizer R&D UK Limited
- Boehringer Ingelheim B.V
- Sanofi Winthrop Industrie
- Sanofi Pasteur SA
- Sanofi Medley Farmacêutica Ltda
- Sanofi Ablynx NV
- Sanofi US
- ViiV Healthcare UK
- National Institute for Health and Care Excellence (NICE)
- The University Court of the University of Aberdeen
- Pfizer Polska